Nexstim Plc (Nexstim” or the “Company”) published its initial public offering (the “Offering”) on 13 October 2014, in which the Company offered for subscription up to 2,873,563 new shares. The Company also announced that it will apply for listing of its shares on Nasdaq First North Finland and Nasdaq First North Sweden. The submission of...
Agreement enhances existing relationship between Celladon and Lonza for the manufacture of MYDICAR®Lonza to initiate design of a new commercial viral therapeutics facility in Portsmouth, NH (USA)         Celladon obtains option to trigger construction of facility and commit to long-term commercial supplyLonza to purchase $10 million of Celladon common stock upon Celladon's decision to trigger construction...
Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that the U.S. Food and Drug Administration has informed Veloxis of the tentative approval of Envarsus® XR.  FDA stated that the final approval of Envarsus XR will be delayed until expiration of the exclusivity period for Astellas' Astagraf XL®.  Veloxis understands that this expiry is anticipated to occur...
New Gene Therapy Approach Shown to Reverse Heart Damage and Improve Long Term Cardiac Function Following Myocardial Infarction in Animal Models
Cambridge, Mass., October 15, 2014 - Cydan Development, Inc., an orphan drug accelerator that identifies and de-risks programs with significant therapeutic and commercial potential, today announced the appointment of Vered Bisker-Leib, Ph.D., MBA, as Chief Business Officer. Dr. Bisker-Leib brings a proven track record of identifying, evaluating and executing business development activities in top-tier companies,...
It is now possible to apply for fellowships within biomedicine and natural sciences. The fellowwhips are awarded for 5 years and amounts to DKK 10 million (approx. 1,3 million Euro) 
Cambridge, UK - 7th October 2014: Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV...
The objective of the PROCRIN program is to enhance the quality and quantity of medical data that can be used for research, diagnosis, and treatment, thereby improving the quality and safety of patient treatment in Denmark. 
Ness Ziona, Israel - September 29, 2014 - Atox Bio, a clinical stage company developing novel immunemodulators for severe infections, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Atox Bio with a contract valued up to $24 million and 4.5 years for the development of AB103 to treat Necrotizing Soft...
New Data presented at the 33rd annual meeting of The European Bone & Joint Society (EBJIS) Lund, Sweden, (PRNEWSWIRE) September 23, 2014 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced new twelve.months follow-up data from an on-going clinical trial investigating...
1 2 3 4 8


The Lundbeck Foundation increases its commitment to IO Biotech
12. January 2021
The Lundbeck Foundation launches 2030 strategy with ambitious goals for grant and commercial activities
22. December 2020
Lundbeck foundation awards grants worth dkk 57 million to bold projects
15. December 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge